<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-27T02:29:48Z</responseDate><request verb="GetRecord" identifier="oai:uvadoc.uva.es:10324/3292" metadataPrefix="etdms">https://uvadoc.uva.es/oai/request</request><GetRecord><record><header><identifier>oai:uvadoc.uva.es:10324/3292</identifier><datestamp>2025-05-07T09:33:30Z</datestamp><setSpec>com_10324_1138</setSpec><setSpec>com_10324_931</setSpec><setSpec>com_10324_894</setSpec><setSpec>col_10324_1226</setSpec></header><metadata><thesis xmlns="http://www.ndltd.org/standards/metadata/etdms/1.0/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.ndltd.org/standards/metadata/etdms/1.0/ http://www.ndltd.org/standards/metadata/etdms/1.0/etdms.xsd">
<title>A Randomized double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease</title>
<creator>Martínez Zapata, María José</creator>
<creator>Moreno, Rosa M.</creator>
<creator>Gich Saladich, Ignasi</creator>
<creator>Urrutia, Gerard</creator>
<creator>Bonfill Cosp, Xavier</creator>
<creator>Vaquero Puerta, Carlos</creator>
<subject>Insuficiencia crónica venosa</subject>
<subject>Calcio</subject>
<description>Producción Científica</description>
<description>Objective. To assess the efficacy of calcium dobesilate on the quality-of-life (QoL) of patients with chronic venous disease&#xd;
(CVD).&#xd;
Design. Randomised, parallel, double blind, placebo-controlled clinical trial.&#xd;
Methods. Patients were recruited from vascular surgery clinics and randomised to 500 mg capsules of calcium dobesilate&#xd;
twice a day for 3 months or placebo. The primary outcome measure was ‘QoL after 3 months’ treatment measured by the&#xd;
specific Chronic Insufficiency Venous International Questionnaire (CIVIQ). Secondary outcomes were QoL at 12 months&#xd;
and assessment of the CVD signs and symptoms. The principal analysis was undertaken on the intention-to-treat (ITT)&#xd;
data.&#xd;
Results. Five hundred and nine patients were recruited (246 to calcium dobesilate and 263 to placebo). The analysis of the&#xd;
‘QoL after 3 months’ showed no significant differences between groups ( p ¼ 0.07). For secondary outcomes, oedema and&#xd;
symptoms of CVD, there were no significant differences between groups. In a multi-factorial analysis, the ‘QoL at 12&#xd;
months’ was better in the calcium dobesilate group than in placebo group ( p ¼ 0.02).&#xd;
Conclusions. Treatment with calcium dobesilate was not found to be superior to placebo on the QoL of CVD patients. The&#xd;
sustained effect of calcium dobesilate observed after treatment should be confirmed in future studies.&#xd;
  2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.</description>
<date>2013-08-02</date>
<date>2013-08-02</date>
<date>2008</date>
<type>info:eu-repo/semantics/article</type>
<identifier>European Journal Vascular Endovascular Surgery, March 2008, n. 35. p.358-365</identifier>
<identifier>1078-5884</identifier>
<identifier>http://uvadoc.uva.es/handle/10324/3292</identifier>
<identifier>10.1016/j.ejvs.2007.08.012</identifier>
<identifier>358</identifier>
<identifier>35</identifier>
<identifier>365</identifier>
<identifier>European Journal Vascular Endovascular Surgery</identifier>
<language>eng</language>
<relation>https://www.sciencedirect.com/science/article/pii/S1078588407005515</relation>
<rights>info:eu-repo/semantics/openAccess</rights>
<rights>http://creativecommons.org/licenses/by-nc-nd/3.0/</rights>
<rights>© 2008 Elsevier</rights>
<rights>Attribution-NonCommercial-NoDerivs 3.0 Unported</rights>
<publisher>Elsevier</publisher>
</thesis></metadata></record></GetRecord></OAI-PMH>